AI Summary Empagliflozin (Jardiance) is a once-daily tablet that lowers blood glucose by making the kidneys release more glucose in urine.
Medically reviewed.
Empagliflozin (Jardiance) is a prescription sodium-glucose cotransporter 2 (SGLT2) inhibitor approved to improve glycemic control in adults with type 2 diabetes. In clinical studies, empagliflozin has also demonstrated a reduced risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. Because obesity, insulin resistance, and type 2 diabetes are closely linked to MASLD and MASH, some healthcare providers may consider empagliflozin for eligible patients to help manage these underlying metabolic risk factors, even though it is not FDA-approved specifically for liver disease. Treatment decisions should always be individualized and guided by a healthcare professional.
This page covers empagliflozin's role in metabolic and MASLD/MASH management — how it works, who may be eligible, benefits, side effects, and monitoring. You can also connect with a liver specialist near you for personalized guidance on whether empagliflozin fits your care plan.
Liver Health AI Assistant
Ask Aimy
Aimy answers from LiverDirectory’s reviewed health information — helping patients make sense of liver-health terms, prepare for specialist visits, and explore what to look up next.
ABOUT EMPAGLIFLOZIN TREATMENT
Empagliflozin is a prescription medicine sold under the brand name Jardiance. It belongs to a class of medications called sodium-glucose cotransporter 2 (SGLT2) inhibitors, which work in the kidneys rather than the liver or pancreas.
Empagliflozin is approved to improve glycemic control in adults with type 2 diabetes. In clinical studies, it has also been shown to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. Because obesity, insulin resistance, and elevated blood sugar are closely linked to MASLD and MASH, some healthcare providers may consider empagliflozin to help manage these underlying metabolic risk factors, even though it is not FDA-approved specifically for liver disease.
It is typically used as part of a broader, personalised treatment plan that may include dietary changes, physical activity, and regular monitoring by your healthcare provider, such as Liver Function Tests (LFTs) or imaging.
WHO EMPAGLIFLOZIN MAY BE SUITABLE FOR
Eligibility for empagliflozin depends on the medication's approved uses, your diagnosis, and your individual health needs. Empagliflozin is approved to improve glycemic control in adults with type 2 diabetes, so it may be considered for people who meet this criteria and who require additional blood glucose control, have cardiovascular disease risk factors or established cardiovascular disease, or need pharmacologic therapy for glycemic management. Some healthcare providers may also consider empagliflozin for eligible patients with MASLD or MASH linked to these metabolic risk factors.
Your medical history, current health status, liver condition, kidney function, and any other medications you take all factor into whether empagliflozin is an appropriate option for you.
Because every patient's health profile is different, there is no one-size-fits-all answer to who should take empagliflozin. Treatment decisions are individualized and should be made by a qualified healthcare professional after a full assessment of your metabolic health, liver condition, and treatment goals. Your doctor will weigh the potential benefits against any risks before determining whether empagliflozin fits safely into your broader care plan.
ELIGIBILITY OVERVIEW
Empagliflozin may be considered for adults with the following conditions, risk factors, or treatment goals:
Before recommending empagliflozin, healthcare providers evaluate several factors to determine whether it is an appropriate option, including:
HOW EMPAGLIFLOZIN CAN HELP YOUR LIVER
Empagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubules, reducing how much glucose the kidneys reabsorb back into the blood. This causes excess glucose to be excreted in the urine, which lowers blood glucose levels in adults with type 2 diabetes.
This kidney-based mechanism differs from GLP-1 medications such as Ozempic, which act on the pancreas and stomach, or Resmetirom, which acts directly on liver cells. Empagliflozin does not directly target the liver, but by lowering blood glucose and modestly supporting weight loss, it may help address some of the metabolic drivers behind MASLD and MASH.
For patients with type 2 diabetes and metabolic risk factors, these effects can support treatment goals such as better blood sugar control, reduced cardiovascular risk, and kidney protection. Empagliflozin is not used on its own — providers pair it with dietary changes, physical activity, and regular monitoring, such as blood glucose checks and Liver Function Tests (LFTs), to support these outcomes.
LIVER BENEFITS
Insulin resistance and type 2 diabetes are closely linked to MASLD and MASH. Empagliflozin lowers blood glucose through the kidneys, so providers may use it to address one of these underlying drivers. It does not act directly on liver cells.
Extra weight, especially around the belly, raises the risk of MASLD. Empagliflozin may support modest weight loss when combined with diet and exercise, which fits into a broader plan to manage weight-related liver risk.
Cardiovascular disease is the leading cause of death among people with MASLD. In adults with type 2 diabetes and established cardiovascular disease, empagliflozin has been shown to reduce the risk of cardiovascular death.
MASLD often occurs alongside chronic kidney disease. Because empagliflozin may help slow kidney disease progression in eligible patients, your provider may weigh kidney health when choosing therapy for metabolic liver disease.
Empagliflozin lowers blood glucose through the kidneys and supports cardiovascular and kidney health, which may indirectly help people with MASLD or MASH linked to diabetes. It is not a direct liver treatment and should only be started and monitored under the guidance of a qualified healthcare professional.
TREATMENT PROCESS
Empagliflozin (Jardiance) is supplied as an oral tablet. Take it exactly as prescribed by your healthcare provider, and check with your pharmacist if you have any questions about your specific tablet strength.
The typical dose is 10 mg once daily, which may be increased to 25 mg once daily depending on treatment response and tolerability. Your healthcare provider determines the right dose and any adjustments based on how you respond.
Empagliflozin is a once-daily oral tablet — it is not an injection or infusion. Take it with or without food, at the same time each day. Maintain adequate hydration while taking this medication, since it increases urination.
Empagliflozin is generally used as a long-term therapy for type 2 diabetes and associated cardiovascular or kidney risk reduction, rather than a short-term course. Continue treatment as prescribed, and do not stop taking it without first talking to your healthcare provider.
Store empagliflozin tablets at room temperature, away from moisture and heat.
Your healthcare provider will regularly monitor blood glucose levels, kidney function, hydration status, and overall treatment response. For people using empagliflozin alongside MASLD or MASH management, providers may also monitor liver health measures, such as Liver Function Tests (LFTs), alongside routine follow-up. Report any side effects or unusual symptoms to your healthcare provider.
BENEFITS AND SAFETY
Empagliflozin (Jardiance) may support people with type 2 diabetes and metabolic risk factors linked to MASLD and MASH by lowering blood glucose through increased urinary glucose excretion. It has also demonstrated cardiovascular and kidney benefits in clinical studies, which can matter for people managing metabolic liver disease alongside diabetes and heart disease risk. The extent of these benefits varies from person to person, depending on their liver condition, overall metabolic health, treatment plan, and how their body responds to therapy. Empagliflozin is not a direct liver treatment — it works best as part of a broader, personalised care plan that combines the medication with lifestyle changes, such as a liver-healthy diet and regular physical activity, along with ongoing monitoring like Liver Function Tests (LFTs) or imaging.
As with any medication, empagliflozin may cause side effects, ranging from urinary and genital infections to dehydration and dizziness. Your healthcare provider will assess whether empagliflozin is a suitable option for you and will monitor your treatment response throughout therapy, adjusting the dose or overall care plan as needed to balance potential benefits against any risks.
BENEFITS
Empagliflozin helps lower blood glucose levels and improve diabetes management, addressing a key metabolic risk factor linked to MASLD and MASH.
Empagliflozin may promote modest weight loss when combined with diet and exercise, which can help reduce liver fat over time.
Empagliflozin has been shown to reduce certain heart-related risks, including cardiovascular death, in adults with type 2 diabetes and established cardiovascular disease.
Empagliflozin may help slow the progression of kidney disease in eligible patients, offering protective benefits relevant to people managing metabolic liver disease.
These effects are often more noticeable when starting treatment and may improve over time. Your healthcare provider will discuss the potential benefits and risks before treatment and provide ongoing support, including hydration guidance, to ensure safe use.
SUPPORTING YOUR RESULTS
Empagliflozin works best when combined with a balanced diet, regular physical activity, weight management, and other lifestyle modifications recommended by your healthcare provider. Good hydration is especially important, since empagliflozin increases urination.
These habits can support how your body responds to treatment and may help improve outcomes over time.
Areas that may support treatment:
COMMON QUESTIONS
Empagliflozin is not FDA-approved as a direct treatment for MASLD or MASH. It is an SGLT2 inhibitor approved to improve glycemic control in adults with type 2 diabetes and to reduce cardiovascular death risk in eligible patients. Because obesity, insulin resistance, and elevated blood sugar are metabolic drivers of MASLD and MASH, some healthcare providers may consider empagliflozin to help manage these underlying risk factors. It does not act directly on the liver, so any use for metabolic liver disease should be guided and monitored by a qualified healthcare professional.
Empagliflozin lowers blood glucose by blocking glucose reabsorption in the kidneys, causing excess sugar to leave the body through urine. Ozempic (semaglutide) is a GLP-1 receptor agonist that acts on the pancreas and stomach to regulate blood sugar and appetite. Resmetirom acts directly on liver cells to reduce fat and inflammation in MASH. Each medication targets a different mechanism, so your healthcare provider will determine which option, if any, fits your diagnosis and treatment goals.
The most common side effects of empagliflozin include urinary tract infections, genital yeast infections, increased urination, dehydration, and dizziness. These effects are often more noticeable when starting treatment and may lessen over time as your body adjusts. Staying well hydrated can help reduce some of these effects. Always report new or worsening symptoms to your healthcare provider, who can adjust your dose or treatment plan and confirm whether empagliflozin remains a safe option for you.
Empagliflozin may promote modest weight loss when combined with a balanced diet and regular physical activity. It is not primarily prescribed as a weight-loss medication, and results vary from person to person depending on overall metabolic health and treatment plan. Because excess weight is linked to fat accumulation in the liver, this modest effect may indirectly support metabolic liver disease management. Talk with your healthcare provider about realistic expectations and how weight changes fit into your broader care plan.
People with significant kidney impairment, a history of frequent urinary or genital infections, or conditions that increase dehydration risk may need closer monitoring or may not be suitable candidates for empagliflozin. Your healthcare provider will review your medical history, kidney function, current medications, and liver condition before prescribing empagliflozin. Because individual health profiles vary widely, only a qualified healthcare professional can determine whether empagliflozin is an appropriate and safe option for your specific situation.
Blood glucose improvements from empagliflozin can often be seen within the first few weeks of treatment, though individual response times vary. Effects on weight, cardiovascular risk, and kidney protection typically develop over a longer period of consistent use combined with lifestyle changes. Empagliflozin is generally used as a long-term therapy rather than a short-term course. Your healthcare provider will monitor your blood glucose, kidney function, and overall response over time to assess how well the treatment is working for you.
Medical disclaimer: LiverDirectory provides educational information and a directory of providers. It does not provide medical advice, diagnosis, or treatment. Always consult a licensed physician regarding any medical condition.
